Tirzepatide
5mg/vial
Dual GLP-1 / GIP receptor agonist for glycemic and metabolic research.
Price per vial
$99.99
5mg/vial
Concentration
5mg/vial
Warehouse
US Domestic
Product Description
Tirzepatide is a synthetic dual agonist of the GLP-1 and GIP receptors. It has been extensively studied in large-scale clinical trials and is the subject of active laboratory research into glucose homeostasis, body-weight regulation, and metabolic function.
Research Overview
Research with tirzepatide centers on its dual incretin mechanism: simultaneous activation of GLP-1 receptors (pancreatic insulin secretion, gastric emptying) and GIP receptors (insulin sensitization, fat metabolism). Studies have documented robust glycemic-control markers and dose-dependent body-composition changes. For laboratory research use only—not for human consumption or therapeutic application.
Research Applications
Certificate of Analysis (Janoshik)
Research Use Only
This product is intended solely for laboratory research and analytical purposes. Not for human consumption or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease. Statements have not been evaluated by the FDA.